Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xenon MRI in Stable Pulmonary Hypertension
NCT06122922Phase 2Withdrawn
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of hyperpolarized xenon gas in pulmonary arterial hypertension (PAH). Primary endpoint: Change in pulmonary vascular function at 1 year. Planned start Mar 2024; status: withdrawn.
02
Drugs
hyperpolarized xenon gas
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06122922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06122922.